Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

OBJECTIVE: We assessed the effectiveness and safety of daclatasvir (DCV) plus sofosbuvir (SOF), with or without ribavirin (RBV), in a large real-world cohort, including patients with advanced liver disease. DESIGN: Adults with chronic HCV infection at high risk of decompensation or death within 12 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Welzel, Tania M, Petersen, Jörg, Herzer, Kerstin, Ferenci, Peter, Gschwantler, Michael, Wedemeyer, Heiner, Berg, Thomas, Spengler, Ulrich, Weiland, Ola, van der Valk, Marc, Rockstroh, Jürgen, Peck-Radosavljevic, Markus, Zhao, Yue, Jimenez-Exposito, Maria Jesus, Zeuzem, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099229/
https://www.ncbi.nlm.nih.gov/pubmed/27605539
http://dx.doi.org/10.1136/gutjnl-2016-312444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099229/
https://www.ncbi.nlm.nih.gov/pubmed/27605539
http://dx.doi.org/10.1136/gutjnl-2016-312444

Ejemplares similares